SCHEMBL407849

SCHEMBL407849

Cc1cc(OCc2ccccc2)cc(C)c1B(O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.55
LMNA P02545 1/20 0.55
PTGS1 P23219 1/20 0.55
SLC6A2 P23975 1/20 0.55
CYP2C19 P33261 1/20 0.55
PTGS2 P35354 1/20 0.55
SLC6A3 Q01959 1/20 0.55
HIF1A Q16665 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
LIPE Q05469 1/20 0.53
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
CYP1A1 P04798 1/20 0.49
CYP19A1 P11511 1/20 0.49
MAOB P27338 6/20 0.49
MRGPRX4 Q96LA9 1/20 0.48
ALOX5 P09917 1/20 0.47
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
FFAR1 O14842 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29950569 0.83 LIPE (0.54) CYP1A2LMNAPTGS1SLC6A2CYP2C19
SCHEMBL539890 0.83 LIPE (0.54) CYP1A2LMNAPTGS1SLC6A2CYP2C19
SCHEMBL10030221 0.82 CYP1A2 (0.58) CYP1A2LMNAPTGS1SLC6A2CYP2C19
SCHEMBL10903897 0.82 L3MBTL1 (0.55) CYP1A2LMNAPTGS1SLC6A2CYP2C19
SCHEMBL19403065 0.81 MEN1 (0.50) CYP1A2LMNAPTGS1SLC6A2CYP2C19
SCHEMBL3622753 0.81 MEN1 (0.51) MEN1KMT2AMAOBMRGPRX4FFAR1
SCHEMBL31089077 0.81 LIPE (0.55) CYP1A2LMNAPTGS1SLC6A2CYP2C19
SCHEMBL10477402 0.80 APP (0.53) CYP1A2LMNAPTGS1SLC6A2CYP2C19
SCHEMBL1143540 0.80 MAOB (0.53) CYP1A2LMNAPTGS1SLC6A2CYP2C19
SCHEMBL16295658 0.80 LIPE (0.54) CYP1A2LMNAPTGS1SLC6A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-2803664-B1 TETRAHYDROBENZOFURANE DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF DIABETES JIANGSU HENGRUI MEDICINE CO (CN) 2018-11-21 EP disclosed
EP-2831053-B1 NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS BOEHRINGER INGELHEIM INT (DE) 2016-06-22 EP disclosed
US-9139548-B2 Polycyclic derivatives, preparation process and pharmaceutical use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2015-09-22 US disclosed
US-9139548-B2 Polycyclic derivatives, preparation process and pharmaceutical use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2015-09-22 US disclosed
US-9139548-B2 Polycyclic derivatives, preparation process and pharmaceutical use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2015-09-22 US disclosed
CN-103429581-B Many lopps derivative, its preparation method and in application pharmaceutically JIANGSU HENGRUI MEDICINE CO.,LTD. (CN) 2015-08-26 CN disclosed
US-9102642-B2 Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and methods of controlling weeds SYNGENTA LIMITED (GB) 2015-08-11 US disclosed
EP-2393796-B1 NOVEL HERBICIDES SYNGENTA LTD (GB) 2015-02-25 EP disclosed
EP-2831053-A1 NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS Boehringer Ingelheim International GmbH (DE) 2015-02-04 EP disclosed
EP-2393796-A1 NOVEL HERBICIDES Syngenta Limited (GB) 2011-12-14 EP disclosed
US-7786165-B2 Aminophenylpropanoic acid derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-31 US disclosed
US-7786165-B2 Aminophenylpropanoic acid derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-31 US disclosed
US-7786165-B2 Aminophenylpropanoic acid derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-31 US disclosed
WO-2010089210-A1 NOVEL HERBICIDES SYNGENTA LIMITED (GB) 2010-08-12 WO disclosed
WO-2010089211-A1 NOVEL HERBICIDES SYNGENTA LIMITED (GB) 2010-08-12 WO disclosed
US-20080269220-A1 Aminophenylpropanoic Acid Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-20080269220-A1 Aminophenylpropanoic Acid Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-20080269220-A1 Aminophenylpropanoic Acid Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-20040229911-A1 New pharmaceutical combinations for NOS inhibitors PFIZER INC 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269220-A1 Aminophenylpropanoic Acid Derivative GPR119, GPR55, GPR65 CYP1A2 1304/4885LMNA 4270/4885PTGS1 583/4885
US-20040229911-A1 New pharmaceutical combinations for NOS inhibitors NOS1, NOS3, NPBWR1 CYP1A2 1340/4885LMNA 3698/4885PTGS1 1130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.